ABBVIE INC.
XNYS:ABBV
226.44
$232.63 - 1.00
$219.06 - 1.00
$225.05
$229.25
$228.85
$228.71
244.81
164.39
3985188
5685155.7
1765740000
Chart
TendieTensor AI Analysis
Company
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Fundamentals
55,000
172.572248
-151.235200
2.868261
100
BBG0025Y4RY4
BBG0025Y4RZ3
1.77B
1.77B
Technicals
Short Interest
—
—
—
Higher = harder to cover
—
Prev: —
—
—
5D avg: —
—
Discussion
Login to participate in discussions.
Recent News
Related Stocks
Based on the portfolios of people who own ABBV. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.